SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10365	Companies
215861	Keywords
145592	Articles
114303	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 01/22/2025 at 07:00, 1 year 3 months ago

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
EU approves Sarclisa as first anti-CD38 therapy in combination with VRd for transplant-ineligible NDMM based on positive IMROZ study results. Third indication for Sarclisa in the EU

Multiple Myeloma Sarclisa EU Approval VRd Anti-CD38 Therapy
BRIEF

published on 01/15/2025 at 18:35, 1 year 3 months ago

Sanofi : État des droits de vote et actions en novembre 2024

Droits De Vote Actions Informations Réglementées Sanofi Novembre 2024
BRIEF

published on 01/15/2025 at 18:35, 1 year 3 months ago

Sanofi: Status of voting rights and shares in November 2024

Voting Rights Actions Regulated Information Sanofi November 2024
PRESS RELEASE

published on 01/15/2025 at 18:30, 1 year 3 months ago

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2024
Annonce du nombre total de droits de vote et d'actions de Sanofi selon les réglementations en vigueur

Autorité Des Marchés Financiers Droits De Vote Actions Investisseurs Sanofi
BRIEF

published on 12/17/2024 at 13:35, 1 year 4 months ago

Sanofi and Teva Announce Promising Phase 2b Results for Duvakitug

Ulcerative Colitis Crohn’s Disease Duvakitug Phase 2b Results Sanofi And Teva Partnership
BRIEF

published on 12/17/2024 at 13:35, 1 year 4 months ago

Sanofi et Teva annoncent des résultats prometteurs de phase 2b pour Duvakitug

Maladie De Crohn Rectocolite Hémorragique Duvakitug Résultats De La Phase 2b Partenariat Entre Sanofi Et Teva
PRESS RELEASE

published on 12/17/2024 at 13:30, 1 year 4 months ago

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Sanofi and Teva announce positive phase 2b results for duvakitug in ulcerative colitis and Crohn's disease, showing promising potential in IBD. Phase 3 development planned

Ulcerative Colitis Sanofi Teva Crohn's Disease Duvakitug
PRESS RELEASE

published on 12/17/2024 at 13:30, 1 year 4 months ago

Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn
Les résultats positifs de phase IIb du duvakitug pour la colite ulcéreuse et la maladie de Crohn ouvrent la voie à un programme de développement de phase III par Sanofi et Teva

Maladie De Crohn Colite Ulcéreuse Duvakitug Phase IIb Sanofi Teva
BRIEF

published on 12/17/2024 at 07:35, 1 year 4 months ago

Sanofi Releases Q4 2024 Aide-mémoire for Financial Modelling

Financial Results Investors Sanofi Aide-mémoire Q4 2024
BRIEF

published on 12/17/2024 at 07:35, 1 year 4 months ago

Sanofi publie son aide-mémoire pour le quatrième trimestre 2024 sur la modélisation financière

Résultats Financiers Investisseurs Sanofi Aide-mémoire 4e Trimestre 2024

Accesswire

Published on 05/07/2026 at 15:15, 53 minutes ago

ACCESS Newswire Launches ACCESS Insights & Analytics, AI-Powered Press Release Scoring Platform
Published on 05/07/2026 at 14:35, 1 hour 33 minutes ago

Worksport (NASDAQ: WKSP) Announces Q1 2026 Earnings Call Date and Launch of Investor Townhall Series
Published on 05/07/2026 at 14:30, 1 hour 38 minutes ago

Rio Grande Resources Announces Results of First Annual General Meeting and Re-Appointments
Published on 05/07/2026 at 14:30, 1 hour 38 minutes ago

Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook
Published on 05/07/2026 at 14:00, 2 hours 8 minutes ago

Adcore to Publish First Quarter 2026 Results on May 14, 2026

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 15:55, 13 minutes ago

MENARINI GROUP: THOMAS CUENI APPOINTED NEW MEMBER OF THE BOARD
Published on 05/07/2026 at 15:28, 40 minutes ago

JOST’s Annual General Meeting approves dividend of EUR 1.50 per share and elects new Supervisory Board member
Published on 05/07/2026 at 15:10, 58 minutes ago

Elevated Materials Appoints Sunit Kapur as Chief Operating Officer
Published on 05/07/2026 at 15:05, 1 hour 3 minutes ago

CELEBRATING FEET WITH A TOUCH OF COLOR: BIRKENSTOCK INTRODUCES NAIL POLISH COLLECTION
Published on 05/07/2026 at 14:56, 1 hour 12 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Schroders plc

Les Echos

Published on 05/07/2026 at 15:00, 1 hour 8 minutes ago

Déclaration mensuelle du nombre total de droits de vote et du nombre d’actions composant le capital
Published on 05/07/2026 at 07:43, 8 hours 25 minutes ago

ENGIE - Q1 2026 financial information
Published on 05/07/2026 at 07:43, 8 hours 25 minutes ago

ENGIE - Information Financière 1er trimestre 2026
Published on 05/06/2026 at 18:00, 22 hours 8 minutes ago

Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 22 hours 8 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026

View all LES ECHOS COMFI WIRE